We recently published on a TAT-conjugated, bivalent, high-affinity PICK1 inhibitor (TPD5) displaying robust efficacy in the SNI model of neuropathic pain and CFA model of inflammatory pain following i.t. administration in mice (8, 22). Here, PICK1 is linked to neuropathic pain.